ArticleNPJ biofilms and microbiomes2025
Synthesis and antibacterial evaluation of trisindolines against methicillin-resistant Staphylococcus aureus targeting cell membrane.
Article in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant global health threat that requires novel antimicrobials to combat this WHO-designated priority pathogen. In this study, we designed, synthesized and evaluated a series of unexplored trisindoline derivatives against MRSA, including multidrug-resistant (MDR) clinical isolates. The Structure Activity Relationship (SAR) analysis of the trisindolines indicated the importance of strategic substitutions in the trisindoline core for their anti-staphylococcal efficacy. Biocompatibility studies revealed a high safety profile for the active compounds across various mammalian cell lines. Furthermore, the derivatives displayed rapid bactericidal action, anti-biofilm efficacy, intracellular MRSA killing and combinatorial effect with vancomycin. Mechanistic studies revealed that these compounds disrupt MRSA cell integrity by influencing several membrane-related pathways. Finally, in vivo assessments of a lead trisindoline in an MRSA-induced systemic infection model demonstrated a significant reduction of bacterial load. Therefore, these trisindoline molecules may offer a promising therapeutic model for combating MRSA infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.